Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study

Punzi, Henry; Punzi, Connie F.

doi:10.1038/sj.jhh.1001704

Cited by 13 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were no significant differences in the percentage of patients with controlled blood pressure at the end of the study regarding the use of eprosartan monotherapy or combined therapy, although the percentage was slightly higher in the combined therapy group (66 vs. 61%). This finding is consistent with results of other studies in which additional pressure control was achieved when eprosartan was given in combination with hydrochlorothiazide (20–22).…”

Section: Discussionsupporting

confidence: 92%

Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients

Robles

Martín-Águeda

López‐Muñoz

et al. 2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

A multicentre, prospective, non-comparative open-label study was conducted to assess the effect of eprosartan, 600 mg/day, on pulse pressure (PP) in patients with hypertension (stage I or II, Joint National Committee, sixth report) treated in the primary care setting, as well as safety and compliance. The duration of treatment was 16 weeks. Eprosartan decreased PP (-13 mmHg), systolic blood pressure (SBP) (-26 mmHg), diastolic blood pressure (DBP) (-13 mmHg) and mean arterial pressure (MAP) (-17.4 mmHg) significantly (p < 0.0001). The PP/MAP ratio changed significantly from 62 to 59%, so that the reduction of PP was 3% higher than the overall decrease in MAP. Twenty adverse events, mostly gastrointestinal complaints, were recorded in 12 patients (1.9%). Compliance with treatment at the end of the study was 94%. Eprosartan was a well-tolerated and an effective drug in reducing PP, SBP and DBP below the recommended levels in patients with mild-to-moderate essential hypertension, allowing a high therapeutic compliance.

show abstract

Section: Discussionsupporting

confidence: 92%

Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients

Robles

Martín-Águeda

López‐Muñoz

et al. 2005

International Journal of Clinical Practice

View full text Add to dashboard Cite

show abstract

“…Elevated PP may predispose patients with ISH to increased risks compared with those with systolic-diastolic hypertension. Punzi and Punzi showed a reduction in mean PP of 16.9 mmHg with eprosartan versus 9.1 mmHg with placebo in a 13-week study in elderly patients with ISH [31]. Similarly, in a 10-week open-label study in elderly patients, eprosartan was associated with a reduction in PP of 12.5 mmHg in ISH patients versus 8.4 mmHg in patients with systolic-diastolic hypertension [32].…”

Section: Pulse Pressurementioning

confidence: 96%

“…In short-term, placebo-controlled trials, eprosartan was associated with significantly greater reductions in sitting SBP (sitSBP) compared with placebo in patients with mild-to-moderate hypertension [29,30] and in elderly patients with ISH [31,32]. A number of studies have compared the effects of eprosartan with the ACE inhibitor enalapril on SBP.…”

Section: Systolic Blood Pressurementioning

confidence: 99%

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline

Ram¹,

Rudmann²

2007

Expert Review of Cardiovascular Therapy

View full text Add to dashboard Cite

Hypertension is a common condition associated with considerable morbidity and mortality. Antihypertensive drugs reduce the risk of cardiovascular and cerebrovascular events, and may also be associated with reductions in cognitive decline. Eprosartan is an angiotensin II type 1 receptor antagonist with a unique dual mechanism of action that is approved for the treatment of essential hypertension. In clinical trials, eprosartan has been shown to significantly reduce systolic blood pressure and to be associated with significant reductions in pulse pressure in elderly patients with isolated systolic hypertension. Data suggest that blood pressure reductions achieved with eprosartan in elderly hypertensive patients are also associated with improvements in cognitive function. Eprosartan compares favorably with other classes of antihypertensive agents in terms of reductions in mortality, cardiovascular and cerebrovascular events, and stroke recurrence. Evidence suggests that eprosartan may represent a useful addition to combination drug strategies for the management of hypertensive patients with elevated cardiovascular and cerebrovascular risk.

show abstract

“…Eprosartan has been shown to be an effective agent in the elderly. In a double-blind study versus placebo in 283 elderly patients with a mean age of 70 years eprosartan once-daily at doses of 600-1200mg during 3 months produced a significant reduction in systolic blood pressure (eprosartan vs. placebo: 16 and 8 mmHg, p<0.0001) [40]. For patients who did not respond to eprosartan alone, the addition of hydrochlorothiazide provided additive reduction in systolic blood pressure (eprosartan vs. placebo: 22 and 14 mmHg, p<0.002).…”

Section: Eprosartan In Clinical Practicementioning

confidence: 99%

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker

Blankestijn

Rupp²

2008

CHAMC

View full text Add to dashboard Cite

Rationale. The goal of antihypertensive treatment is to reduce risk of cardiovascular morbidity and mortality. Apart from blood pressure lowering per se, also reducing the activities of the renin-angiotensin system and sympathetic nervous system appears to be important. Angiotensin II receptor blocker drugs (ARBs) have provided a useful class of anti-hypertensive drugs. Eprosartan is a relatively new ARB which is chemically distinct (non-biphenyl, non-tetrazole) from all other ARBs (biphenyl tetrazoles). An analysis has been made on available experimental and clinical data on eprosartan which not only is an effective and well tolerated antihypertensive agent, but also lowers the activities of the renin-angiotensin system and sympathetic nervous system. Experimental and pharmacokinetic studies on eprosartan have shown differences with the other ARBs. The distinct properties of this non-biphenyl, non-tetrazole ARB might be relevant in the effort to reduce cardiovascular risk, also beyond its blood pressure lowering capacity.

show abstract

Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study

Cited by 13 publications

References 19 publications

Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients

Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients

Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker

Contact Info

Product

Resources

About